Onderzoeker
Debby Thomas
- Disciplines:Laboratoriumgeneeskunde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Andere medische en gezondheidswetenschappen, Medische biotechnologie, Ontdekking en evaluatie van geneesmiddelen, Farmaceutica
Affiliaties
- Therapeutische en Diagnostische Antilichamen (Afdeling)
Lid
Vanaf1 jun 2017 → Heden - Gynaecologische Oncologie (Afdeling)
Lid
Vanaf1 mrt 2014 → 31 mei 2017
Projecten
1 - 2 of 2
- Symmetrische antilichamen voor symmetrische epitopen: ontwikkeling en validatie van het Symbody platvorm.Vanaf1 okt 2021 → HedenFinanciering: IOF - technologie validatie in labo
- Ontrafeling van de conformatie en oligomerisatie-eigenschappen van proteïne Tau: Aanzet tot innovatieve therapeutische, prognostische en diagnostische strategieënVanaf1 jan 2021 → HedenFinanciering: IOF - technologie validatie in labo
Publicaties
1 - 10 van 34
- Point-of-care therapeutic drug monitoring of adalimumab by integrating a FO-SPR biosensor in a self-powered microfluidic cartridge(2022)
Auteurs: Henry Ordutowski, Charlotte Van Tricht, Mattijs Bulcaen, Marta Ciwinska, Carolina Gutierrez Cisneros, Xander Janssens, Nick Geukens, Debby Thomas, Francesco Dal Dosso, Dragana Spasic, et al.
Aantal pagina's: 9 - Development and validation of a microfluidic multiplex immunoassay for the determination of levels and avidity of serum antibodies to tetanus, diphtheria and pertussis antigens(2022)
Auteurs: Debby Thomas, Louanne Ampofo, Nick Geukens, Xavier Bossuyt
Aantal pagina's: 11 - Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases(2022)
Auteurs: Debby Thomas, Séverine Vermeire, Peter Bossuyt
Pagina's: 208 - 217Aantal pagina's: 10 - The value of therapeutic drug monitoring to guide treatment optimisation of biologicals in patients with chronic inflammatory diseases: focus on vedolizumab and ustekinumab(2021)
Auteurs: Nathalie Van den Berghe, Paul Declerck, Séverine Vermeire, Debby Thomas
- Precise sample metering method by coordinated burst action of hydrophobic burst valves applied to dried blood spot collection(2021)
Auteurs: Dries Vloemans, Lorenz Van Hileghem, Wannes Verbist, Debby Thomas, Francesco Dal Dosso, Jeroen Lammertyn
Pagina's: 1 - 10 - Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model(2021)
Auteurs: Erwin Dreesen, Debby Thomas
Pagina's: 1587 - 1587 - Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations(2021)
Auteurs: Nathalie Van den Berghe, Bram Verstockt, João Pedro Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Paul Declerck, Debby Thomas
Pagina's: 988 - 993 - The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases(2021)
Auteurs: Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, Debby Thomas, Séverine Vermeire, Marc Ferrante, Erwin Dreesen
Pagina's: 3776 - 3789Aantal pagina's: 14 - Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission(2021)
Auteurs: Erwin Dreesen, Debby Thomas
Pagina's: 111 - +Aantal pagina's: 18 - Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients(2020)
Auteurs: Debby Thomas, Kristel Van Steen, Marc Hoylaerts, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pagina's: 819 - 825Aantal pagina's: 7